CapsoVision Raises $14M via 5% Discounted Private Placement Financing
CapsoVision closed a $14 million private placement by selling 2,867,089 shares at $4.883 each, a 5% discount to the March 16 closing price. Preliminary unaudited fourth-quarter revenue was $3.9 million and full-year 2025 revenue totaled $13.6 million with $10.1 million in cash and investments as of December 31, 2025.
1. Private Placement Financing
The company closed a $14 million private placement on March 16, issuing 2,867,089 common shares at $4.883 each, representing a 5% discount to the prior closing price and generating approximately $14 million in gross proceeds from accredited investors.
2. Preliminary Financial Results
Preliminary unaudited results for the fourth quarter showed revenue of $3.9 million, while full-year revenue reached $13.6 million and cash, cash equivalents, restricted cash and investments stood at $10.1 million as of December 31, 2025.
3. Use of Proceeds and Pipeline
Net proceeds are earmarked for general corporate purposes, including sales and marketing, research and development, and working capital, with a focus on advancing the CapsoCam Colon and CapsoCam UGI products and enhancing AI-driven diagnostic capabilities.